Businesses for Sale and Investment

Deep biotech company incubated by a leading university. - We have developed a portable device with AI-powered image recognition capabilities that can analyze Full Blood Count tests. The device will help with monitoring a patient's health from home for conditions such as leukemia and other types of cancer. - Patient can run the tests from their home and once the sample is analyzed, the results are deployed to our platform (app and browser), which is only shared with the designated doctor. - We also provide sophistical tools that help the patient and doctors to track and monitor health over time. - Have our own production facility with a capacity for 100 devices per month and the development of the device is already complete. We have also applied for a patent in the UK. - Revenue model: We will charge a monthly subscription of GBP 1,000 for medical professionals and doctors, and GBP 100 for patients. - Cost of production of each unit is around GBP 1,200 and we have already targeted the production of 1,000 pieces for the launch. - Well-experienced team of experts and medical consultants with over 30 years of industry experience.

The company is selling perpetual usage rights of an AI platform that analyzes microbiome and health data to deliver personalized nutrition and wellness plans. - Partners can deploy and white-label the platform locally, offering premium, data-driven health solutions under their own brand. - The sale includes the proprietary core AI algorithms and source code for the microbiome-based precision diet technology. - Partners receive the right to unlimited API access and the ability to customize and train the AI with local data, ensuring relevance and effectiveness in their market. - The license also grants the right to localized deployment on the partner's local servers for compliance and security, and the autonomy to operate and brand the AI as their own. - The capacity of the AI model is virtually unlimited as it is scalable to the partner's server infrastructure, and its condition is excellent, being actively maintained by us. - The tangible assets required for the operation are minimal and fall primarily under the partner's operational responsibility, reflecting a lean, software-driven business model. - The partner is responsible for managing the inventory of sample collection kits (optional cost of GBP 7.5 per kit), requiring only a small fulfillment/warehouse space for storage and shipping. - We have successfully validated our technology on a global scale, processing over 50,000 microbiome samples across 15+ countries and securing strategic partnerships with major industry players. - Our deep-tech innovation has been recognized with prestigious global awards, including the UK Tech Rocketship Award and victories in the Sanofi and Bayer accelerator programs, establishing us as a trusted leader in the personalized health sector. - The business is driven by a seasoned leadership team, including a serial entrepreneur CEO and a CTO with 15+ years of bioinformatics expertise, ensuring clinical validity and robust architecture. - You can establish a high-margin, end-to-end health service by integrating our software with local Next-Generation Sequencing (NGS) laboratories. - In this model, our partner manages the complete value chain: collecting biological samples, processing them locally, and utilizing our AI to generate premium precision diet and health reports. - These complete diagnostic packages are then sold directly to consumers, medical clinics, and hospitals, allowing the partner to capture the full market value of every test performed. - Alternatively, you can leverage your exclusive regional rights to create a scalable B2B sublicensing ecosystem. - Acting as a master distributor, one can sublicense the software access to other local laboratories, wellness apps, and healthcare networks within the territory. - This allows to generate significant recurring revenue by charging own clients for API access or white-labeled portals, effectively monetizing the technology across the entire region without needing to manage every sample personally. - The company is headquartered in London, while the promoter is currently based in the US and has provided that number for all communications.

The company is selling perpetual usage rights of an AI platform that analyzes microbiome and health data to deliver personalized nutrition and wellness plans. - Partners can deploy and white-label the platform locally, offering premium, data-driven health solutions under their own brand. - The sale includes the proprietary core AI algorithms and source code for the microbiome-based precision diet technology. - Partners receive the right to unlimited API access and the ability to customize and train the AI with local data, ensuring relevance and effectiveness in their market. - The license also grants the right to localized deployment on the partner's local servers for compliance and security, and the autonomy to operate and brand the AI as their own. - The capacity of the AI model is virtually unlimited as it is scalable to the partner's server infrastructure, and its condition is excellent, being actively maintained by us. - The tangible assets required for the operation are minimal and fall primarily under the partner's operational responsibility, reflecting a lean, software-driven business model. - The partner is responsible for managing the inventory of sample collection kits (optional cost of GBP 7.5 per kit), requiring only a small fulfillment/warehouse space for storage and shipping. - We have successfully validated our technology on a global scale, processing over 50,000 microbiome samples across 15+ countries and securing strategic partnerships with major industry players. - Our deep-tech innovation has been recognized with prestigious global awards, including the UK Tech Rocketship Award and victories in the Sanofi and Bayer accelerator programs, establishing us as a trusted leader in the personalized health sector. - The business is driven by a seasoned leadership team, including a serial entrepreneur CEO and a CTO with 15+ years of bioinformatics expertise, ensuring clinical validity and robust architecture. - You can establish a high-margin, end-to-end health service by integrating our software with local Next-Generation Sequencing (NGS) laboratories. - In this model, our partner manages the complete value chain: collecting biological samples, processing them locally, and utilizing our AI to generate premium precision diet and health reports. - These complete diagnostic packages are then sold directly to consumers, medical clinics, and hospitals, allowing the partner to capture the full market value of every test performed. - Alternatively, you can leverage your exclusive regional rights to create a scalable B2B sublicensing ecosystem. - Acting as a master distributor, one can sublicense the software access to other local laboratories, wellness apps, and healthcare networks within the territory. - This allows to generate significant recurring revenue by charging own clients for API access or white-labeled portals, effectively monetizing the technology across the entire region without needing to manage every sample personally. - The company is headquartered in London, while the promoter is currently based in the US and has provided that number for all communications.

At Arth Ayurveda, we believe Ayurveda is the ideal way of life for the 21st century. Our mission is to provide flawless vedic treatment by a team of dedicated professionals. We believe in creating a patient oriented fully integrated healthcare delivery system. We are one of a kind Panchakarma treatment center in Bangalore. We imbibe the logic of natural medication in our treatments on a daily basis, giving a comprehensive and authentic Ayurvedic medication to all the patients.

Company and product: Enbiosis has developed an advanced artificial intelligence algorithm that analyzes the human gut microbiome and recommends personalized food and supplements to individuals to improve their gut health and address chronic disorders such as gastrointestinal disorders, skin-related disorders, and weight loss issues. - How it works: Patients/customers send their stool samples to any NGS laboratory in their region. Enbiosis takes the raw bacterial DNA data to the local server (to avoid data protection risks) and creates a personalized report, which is sent to patients and, if required, their practitioners within minutes. - Business model: Enbiosis's microbiome test can be sold through practitioners and/or directly to customers, depending on market dynamics. Practitioners can prescribe the test to patients to generate a personalized diet plan, or patients can follow their personalized nutrition guide through the app to improve general well-being and solve their problems. - Main differentiation: Enbiosis is the only clinically proven precision diet technology that claims to address the main cause of chronic disorders. It has conducted three clinical trials and published the results in peer-reviewed journals. Enbiosis's claims are backed by scientific evidence. - The main reason why investors should consider Enbiosis: In recent years, the number of people seeking to address their health problems through alternative methods instead of pharmaceuticals has been increasing. The challenge in alternative medicine is the lack of scientific data. Enbiosis serves as a bridge between alternative medicine and conventional medicine, and there is significant market potential for Enbiosis. For example, Enbiosis has proven the effectiveness of its technology in patients with IBS, who make up about 10% of the population. Offering individuals the opportunity to solve their chronic problems simply by changing their diet within a specific period is something they are interested in and willing to try. - Additionally, investors/distributors can offer a routine follow-up program to check gut health and prevent any kind of diseases, opening the door to long-term recurring revenue. - We have a trade registration certificate to operate.

We are a London based manufacturer and supplier of dental implants. - We manufacture surgical devices which is used to replace missing teeth. - Our manufacturing capacity is around 150,000 dental implants per annum. - Have our distribution network in UAE, Saudi Arabia, Oman, Yemen, Taiwan, India. - Company is managed by highly qualified experts and professionals in the field of maxillary, prosthodontic and periodontal surgery. - Have completed the company set up and have an inventory worth GBP 200,000. We need funds to market our product worldwide. - We received a huge influx of clients this year which increased our revenue to an all-time high. The valuation is based on our own estimate.